tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Diekmann F et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. 2001 Nov-Dec Transplant. Proc. pmid:11750386
Sterneck M et al. Steroid withdrawal in long-term liver transplant recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750398
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Ramos-Cebrián M et al. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. 2007 Transplant. Proc. pmid:17889154
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
van Duijnhoven E et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. 1998 Transplant. Proc. pmid:9636514
López Lago AM et al. Evolution of hepatorenal syndrome after orthotopic liver transplantation: comparative analysis with patients who developed acute renal failure in the early postoperative period of liver transplantation. 2007 Transplant. Proc. pmid:17889176
van Duijnhoven E et al. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. 1998 Transplant. Proc. pmid:9636515
García Meseguer C et al. Anti-HLA antibodies posttransplantation in children: do we know what it means? 2009 Jul-Aug Transplant. Proc. pmid:19715846
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
Crespo M et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. 2009 Jul-Aug Transplant. Proc. pmid:19715848
Kedzierska K et al. Oxidative stress indices in rats under immunosuppression. 2011 Transplant. Proc. pmid:22172876
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Riveiro-Barciela M et al. Hyperkalemic distal renal tubular acidosis caused by immunosuppressant treatment with tacrolimus in a liver transplant patient: case report. 2011 Transplant. Proc. pmid:22172892
Pascual J and Ortuño J Simple tacrolimus-based immunosuppressive regimens following renal transplantation: a large multicenter comparison between double and triple therapy. 2002 Transplant. Proc. pmid:11959198
Pascual J et al. One-center comparison between primary immunosuppression based on neoral cyclosporine and tacrolimus for renal transplantation. 2002 Transplant. Proc. pmid:11959200
Stephens J et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. 1993 Transplant. Proc. pmid:7680144
Sumpio BE and Phan S Nephrotoxic potential of FK 506. 1991 Transplant. Proc. pmid:1721278
Fukushima N et al. Histological findings in heart grafts after orthotopic pig to baboon cardiac transplantation. 1996 Transplant. Proc. pmid:8623400
Bilbao I et al. Experience with neoral cyclosporine through the oral route in liver transplantation. 1998 Transplant. Proc. pmid:9636580
Braun F et al. An ex vivo model to study the intestinal biotransformation of immunosuppressive drugs. 2000 Transplant. Proc. pmid:11120037
Oltean M et al. Transplantation of preconditioned intestinal grafts is associated with lower inflammatory activation and remote organ injury in rats. 2006 Jul-Aug Transplant. Proc. pmid:16908278
Tan HP et al. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation. 2005 Transplant. Proc. pmid:16387087
Chen YH et al. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. 2005 Transplant. Proc. pmid:16387090
Nishimori H et al. Combination therapy with FK 506 and splenectomy may induce tolerance in cardiac xenografts. 1994 Transplant. Proc. pmid:7518102
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Lentine KL et al. Variation in Comedication Use According to Kidney Transplant Immunosuppressive Regimens: Application of Integrated Registry and Pharmacy Claims Data. Transplant. Proc. pmid:26915843
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Zhao DQ et al. Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review. Transplant. Proc. pmid:26915834
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Kita J et al. Effects of tacrolimus on small and large bowel anastomoses in the rat. 1999 Transplant. Proc. pmid:10578292
Azuma T et al. Study of graft-infiltrating cells in the rat small bowel allograft using low-dose FK 506. 1999 Transplant. Proc. pmid:10578293
Andres A et al. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation. 2005 Transplant. Proc. pmid:15848711
Petan JA et al. Physiochemical properties of generic formulations of tacrolimus in Mexico. 2008 Transplant. Proc. pmid:18589125
Figueras J et al. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. 2002 Transplant. Proc. pmid:12176461
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Bäckman L et al. Steroid-free immunosuppression in kidney transplant recipients and prograf monotherapy: an interim analysis of a prospective multicenter trial. 2006 Transplant. Proc. pmid:17098029
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Rintala JM et al. The effect of FK778 on acute rat renal allograft rejection and expression of platelet-derived growth factor and transforming growth factor-beta. 2006 Transplant. Proc. pmid:17098049
Takahashi K et al. Successful results after 5 years of tacrolimus therapy in ABO-incompatible kidney transplantation in Japan. 2005 Transplant. Proc. pmid:15919471
Foroncewicz B et al. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center. 2009 Transplant. Proc. pmid:19857686
Zhou W et al. Calcineurin inhibitors block B-1 cell differentiation: the relevance to immunosuppressive treatment in ABO-incompatible transplantation. 2005 Transplant. Proc. pmid:15919474
Niel OR et al. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. 2009 Transplant. Proc. pmid:19857743
Soin AS et al. Complement activation during rejection in experimental intestinal transplantation. 1997 Transplant. Proc. pmid:9142282
Lin YH et al. The 4-week serum creatinine level predicts long-term renal dysfunction after adult living donor liver transplantation. 2012 Transplant. Proc. pmid:22483492
Rossi G et al. Small bowel transplantation under oral immunosuppression: experimental study in the pig. 1997 Transplant. Proc. pmid:9142285
Charco R et al. Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression. 2002 Transplant. Proc. pmid:12176482
Chen CL et al. FK 506 used as rescue therapy for refractory liver allograft rejection. 1994 Transplant. Proc. pmid:7520612
Cheng CY et al. Intervention of Online Percent Coefficient of Variation Reporting System Reduces the Variability of Tacrolimus Trough Concentration in Kidney Transplant Recipients. 2018 Transplant. Proc. pmid:30316366
Nakata S et al. Immunosuppressive mechanisms of deoxymethylspergualin and FK 506 on in vitro cytotoxic T lymphocytes. 1994 Transplant. Proc. pmid:7520613
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Goh BL et al. FK506 rescue therapy for acute renal allograft rejection. 1998 Transplant. Proc. pmid:9838574
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Melk A et al. P-glycoprotein expression in patients before and after kidney transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083115
Watanabe T et al. Effects of the endothelin-1 receptor antagonist TAK-044 on pulmonary injury in discordant xenotransplantation. 2000 Transplant. Proc. pmid:10936270
Veroux P et al. Tacrolimus-induced neurotoxicity in kidney transplant recipients. 2002 Transplant. Proc. pmid:12493415
Katoh H et al. Effectiveness of 15-deoxyspergualin on steroid-resistant acute rejection in living related liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123125
Takeuchi H et al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level. 2008 Transplant. Proc. pmid:18790203
Scolari MP et al. Acute rejection after renal transplantation with tacrolimus-based therapy in conditions of normal clinical practice. 2002 Transplant. Proc. pmid:12176529
Chen WY et al. Betel Nut Chewing Is Associated With Reduced Tacrolimus Concentration in Taiwanese Liver Transplant Recipients. 2017 Transplant. Proc. pmid:28219593
Kato H et al. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation. 2016 Transplant. Proc. pmid:27320564
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Zanker B et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083521
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Mohamed MA et al. The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. 1999 Feb-Mar Transplant. Proc. pmid:10083523
Furtado A et al. Local immunosuppression in clinical small bowel transplantation (report of two cases). 2000 Transplant. Proc. pmid:10995910
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Ayar Y et al. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience. 2017 Transplant. Proc. pmid:28219583
Yamagami S et al. Rejection mechanism and immunosuppression by FK 506 and anti-leukocyte function associated antigen-1 antibody in concordant corneal xenotransplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123598
Nagashima N et al. Immunocompetence assay for net effect of combined immunosuppression. 2001 Transplant. Proc. pmid:11377556
Sheng H et al. Ocular complications of heart transplantation in a Chinese population. 2008 Transplant. Proc. pmid:19100445
Baran DA et al. Tacrolimus and cardiac transplantation: a comparison of monotherapy and steroid-dependent patients. 2002 Transplant. Proc. pmid:12176599
Chariat MN et al. Basiliximab in the therapy of acute rejection after organ transplantation. 2001 Transplant. Proc. pmid:11377567
Chan MC et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. 2002 Transplant. Proc. pmid:12176601
Akbas SH et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. 2006 Transplant. Proc. pmid:16797284
Felipe CR et al. Choosing the right dose of new immunossuppressive drugs for new populations: importance of pharmacokinetic studies. 2001 Feb-Mar Transplant. Proc. pmid:11267207
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
Ersoy A et al. Diabetic ketoacidosis following development of de novo diabetes in renal transplant recipient associated with tacrolimus. 2004 Transplant. Proc. pmid:15251345
Lim SM et al. Heterotopic heart transplantation in the rat receiving FK-506. 1987 Transplant. Proc. pmid:2445080
Eberlin M et al. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. 2013 Jul-Aug Transplant. Proc. pmid:23726723
Gatti S et al. Graft-versus-host reaction and graft rejection after liver, small bowel or small bowel allotransplantation in the pig. 1998 Transplant. Proc. pmid:9745509
Busuttil RW and Holt CD Tacrolimus is superior to cyclosporine in liver transplantation. 1998 Transplant. Proc. pmid:9723432
Toyoki Y et al. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience. 2004 Transplant. Proc. pmid:15561218
Lo A et al. Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study. 2001 Feb-Mar Transplant. Proc. pmid:11267465
Burke GW et al. Ten-year survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267467
Miki T et al. Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. 1998 Transplant. Proc. pmid:9636444
Kobashigawa JA Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. 1998 Transplant. Proc. pmid:9636445
Wong YT et al. Audit of diabetes in a renal transplant population. 2005 Transplant. Proc. pmid:16298573
Xie L et al. Pretransplantation Risk Factors Associated With New-onset Diabetes After Living-donor Kidney Transplantation. 2016 Transplant. Proc. pmid:27931572
Mohsin N et al. Pharmacokinetics of mycophenolate mofetil in Omani patients on cyclosporine or tacrolimus. 2015 Transplant. Proc. pmid:26036534
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823